Multiple sclerosis (Houndmills, Basingstoke, England)最新文献

{"title":"Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.","authors":"Henrik Heitmann,&nbsp;Till F M Andlauer,&nbsp;Thomas Korn,&nbsp;Mark Mühlau,&nbsp;Peter Henningsen,&nbsp;Bernhard Hemmer,&nbsp;Markus Ploner","doi":"10.1177/1352458520972279","DOIUrl":"https://doi.org/10.1177/1352458520972279","url":null,"abstract":"<p><p>Fatigue, depression, and pain affect the majority of multiple sclerosis (MS) patients, which causes a substantial burden to patients and society. The pathophysiology of these symptoms is not entirely clear, and current treatments are only partially effective. Clinically, these symptoms share signs of anhedonia, such as reduced motivation and a lack of positive affect. In the brain, they are associated with overlapping structural and functional alterations in areas involved in reward processing. Moreover, neuroinflammation has been shown to directly impede monoaminergic neurotransmission that plays a key role in reward processing. Here, we review recent neuroimaging and neuroimmunological findings, which indicate that dysfunctional reward processing might represent a shared functional mechanism fostering the symptom cluster of fatigue, depression, and pain in MS. We propose a framework that integrates these findings with a focus on monoaminergic neurotransmission and discuss its therapeutic implications, limitations, and perspectives.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1020-1027"},"PeriodicalIF":5.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1352458520972279","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38601055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.","authors":"Lauren Uhr,&nbsp;Farrah J Mateen","doi":"10.1177/13524585211030647","DOIUrl":"https://doi.org/10.1177/13524585211030647","url":null,"abstract":"<p><strong>Background: </strong>Vaccine willingness among people living with multiple sclerosis (PwMS) requires assessment following the approval of the first COVID-19 vaccines, since there remains uncertainty on multiple aspects of COVID-19 vaccination in immunosuppressed patients.</p><p><strong>Objective: </strong>To understand COVID-19 and influenza vaccine willingness and its associations among PwMS, following the approval of the first two mRNA COVID-19 vaccines.</p><p><strong>Methods: </strong>A survey was distributed to PwMS via an online platform from December 2020 to February 2021. Logistic regression models were constructed to determine the relationship between (1) COVID-19 and (2) influenza vaccination willingness with demographic and clinical characteristics.</p><p><strong>Results: </strong>Of 701 responding PwMS, 76.6% were COVID-19 vaccine willing. COVID-19 vaccine willingness was significantly associated with influenza vaccine willingness (<i>p</i> < 0.001). In multivariable models, older age increased the odds of COVID-19 and influenza vaccine willingness (odds ratios (ORs) > 1) and other race decreased the odds of COVID-19 and influenza vaccine willingness (ORs < 1); higher functional disability decreased the odds of COVID-19 vaccine willingness (OR = 0.88, 95% confidence interval = 0.80-0.96). Prevalent vaccine-related concerns include safety (<i>n</i> = 244) and efficacy (<i>n</i> = 122).</p><p><strong>Conclusion: </strong>Our findings identify demographic and clinical factors as well as concerns influencing vaccine hesitancy in PwMS. These results may inform effective public health interventions to improve vaccine acceptability in this at-risk group.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1072-1080"},"PeriodicalIF":5.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211030647","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39230923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.","authors":"Nicolas Maubeuge,&nbsp;Mathilde Sa Deloire,&nbsp;Bruno Brochet,&nbsp;Julie Charré-Morin,&nbsp;Aurore Saubusse,&nbsp;Aurélie Ruet","doi":"10.1177/13524585211054006","DOIUrl":"https://doi.org/10.1177/13524585211054006","url":null,"abstract":"<p><strong>Background: </strong>The Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) is a short neuropsychological battery for persons with multiple sclerosis (PwMS).</p><p><strong>Objectives: </strong>The main objective of the study is to validate the BCCAMS.</p><p><strong>Methods: </strong>PwMS and healthy subjects (HS) were evaluated using the BCCAMS which include two computerized tests, the Computerized Speed Cognitive Test and the Computerized Episodic Visual Memory Test (CEVMT), a newly developed visuospatial memory test, and the French learning test. The Minimal Assessment of Cognitive Function in MS (MACFIMS), including the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) tests, was also administered. Regression-based norms of the BCCAMS were calculated in 276 HS. BCCAMS was compared with BICAMS and MACFIMS for detection of cognitive impairment (CI).</p><p><strong>Results: </strong>Out of 120 PwMS, CI was detected using the BCCAMS, BICAMS (one impaired test), and MACFIMS (two impaired tests) in 59.1%, 50%, and 37.9%, respectively. The BCCAMS produced the same predictive value as that of the BICAMS battery for detecting CI in the MACFIMS.</p><p><strong>Conclusion: </strong>This study validated the BCCAMS as a validated computerized short assessment for information processing speed and learning in MS.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1112-1120"},"PeriodicalIF":5.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.","authors":"Zoë Ygj van Lierop,&nbsp;Alyssa A Toorop,&nbsp;Wouter Jc van Ballegoij,&nbsp;Tom Bg Olde Dubbelink,&nbsp;Eva Mm Strijbis,&nbsp;Brigit A de Jong,&nbsp;Bob W van Oosten,&nbsp;Bastiaan Moraal,&nbsp;Charlotte E Teunissen,&nbsp;Bernard Mj Uitdehaag,&nbsp;Joep Killestein,&nbsp;Zoé LE van Kempen","doi":"10.1177/13524585211028833","DOIUrl":"https://doi.org/10.1177/13524585211028833","url":null,"abstract":"<p><p>In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1121-1125"},"PeriodicalIF":5.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211028833","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39167042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.","authors":"Brian M Sandroff,&nbsp;Robert W Motl,&nbsp;Maria Pia Amato,&nbsp;Giampaolo Brichetto,&nbsp;Jeremy Chataway,&nbsp;Nancy D Chiaravalloti,&nbsp;Gary R Cutter,&nbsp;Ulrik Dalgas,&nbsp;John DeLuca,&nbsp;Rachel Farrell,&nbsp;Peter Feys,&nbsp;Massimo Filippi,&nbsp;Jennifer Freeman,&nbsp;Matilde Inglese,&nbsp;Cecilia Meza,&nbsp;Maria A Rocca,&nbsp;Amber Salter,&nbsp;Anthony Feinstein","doi":"10.1177/13524585211048397","DOIUrl":"https://doi.org/10.1177/13524585211048397","url":null,"abstract":"<p><strong>Background: </strong>Aerobic exercise training (physical activity for improving cardiorespiratory fitness) represents a promising approach for managing cognitive impairment in multiple sclerosis (MS). However, there is limited evidence that levels of physical activity and fitness are associated with cognition in progressive MS.</p><p><strong>Objective: </strong>We examined associations among cardiorespiratory fitness, moderate-to-vigorous physical activity (MVPA), and cognitive performance in a large, international progressive MS sample.</p><p><strong>Methods: </strong>Two hundred forty European and North American persons with progressive MS underwent cardiorespiratory fitness measurement on a recumbent stepper, wore an ActiGraph GT3X + accelerometer for 7 days for measuring MVPA, and underwent the Brief International Cognitive Assessment in MS.</p><p><strong>Results: </strong>Cardiorespiratory fitness was not significantly correlated with Symbol Digit Modalities Test (SDMT; <i>r</i> = -0.01; <i>r</i> = -0.04), California Verbal Learning Test-II (CVLT-II; <i>r</i> = 0.05; <i>r</i> = 0.05), or Brief Visuospatial Memory Test-Revised (BVMT-R; <i>r</i> = -0.14; <i>r</i> = -0.14) <i>z</i>-scores controlling for age, sex, and education. MVPA and SDMT (<i>r</i> = 0.05), CVLT-II (<i>r</i> = -0.07), and BVMT-R (<i>r</i> = 0.01) <i>z</i>-scores were not significantly correlated.</p><p><strong>Conclusion: </strong>Cardiorespiratory fitness and MVPA were not associated with cognition in this large progressive MS sample, yet these outcomes represent critical manipulation checks for documenting the success of the CogEx trial. This highlights the importance of examining other exercise-related mechanisms-of-action for improving cognition in progressive MS.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1091-1100"},"PeriodicalIF":5.8,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39475983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.","authors":"Michelle H Cameron,&nbsp;Andrea Hildebrand,&nbsp;Cinda L Hugos,&nbsp;Grace I Judd,&nbsp;Garnett McMillan,&nbsp;Peter G Jacobs","doi":"10.1177/13524585211046898","DOIUrl":"https://doi.org/10.1177/13524585211046898","url":null,"abstract":"<p><strong>Background: </strong>People with multiple sclerosis (PwMS) fall frequently. Community-delivered exercise and education reduce falls in older adults, but their efficacy in multiple sclerosis (MS) is unknown.</p><p><strong>Objectives: </strong>To evaluate the impact of the Free From Falls (FFF) group education and exercise program on falls in PwMS.</p><p><strong>Methods: </strong>This was a prospective, assessor-blinded, two-arm parallel randomized controlled trial. Ninety-six participants were randomized to FFF (eight weekly 2 hour sessions) or the control condition (a fall prevention brochure and informing their neurologist of their fall history). Participants counted falls prospectively from enrollment through 6 months following intervention. Effects on fall frequency were evaluated by the Bayesian analysis.</p><p><strong>Results: </strong>The modeled mean fall frequency pre-intervention was 1.2 falls/month in the FFF group (95% credible intervals (CIs) = 0.8-2.0) and 1.4 falls/month in the control group (95% CI = 0.9-2.1). Fall frequency decreased by 0.6 falls/month in both groups over time (nadir 4-6 months post-intervention: FFF 0.6 falls/month (95% CI = 0.4-0.9); control 0.8 falls/month (95% CI = 0.5-1.1)).</p><p><strong>Conclusion: </strong>In-person group exercise and education are not superior to written education and neurologist-initiated interventions for preventing falls in PwMS.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"980-988"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39478613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging role of artificial intelligence in multiple sclerosis imaging.","authors":"H M Rehan Afzal,&nbsp;Suhuai Luo,&nbsp;Saadallah Ramadan,&nbsp;Jeannette Lechner-Scott","doi":"10.1177/1352458520966298","DOIUrl":"https://doi.org/10.1177/1352458520966298","url":null,"abstract":"<p><strong>Background: </strong>Computer-aided diagnosis can facilitate the early detection and diagnosis of multiple sclerosis (MS) thus enabling earlier interventions and a reduction in long-term MS-related disability. Recent advancements in the field of artificial intelligence (AI) have led to the improvements in the classification, quantification and identification of diagnostic patterns in medical images for a range of diseases, in particular, for MS. Importantly, data generated using AI techniques are analyzed automatically, which compares favourably with labour-intensive and time-consuming manual methods.</p><p><strong>Objective: </strong>The aim of this review is to assist MS researchers to understand current and future developments in the AI-based diagnosis and prognosis of MS.</p><p><strong>Methods: </strong>We will investigate a variety of AI approaches and various classifiers and compare the current state-of-the-art techniques in relation to lesion segmentation/detection and prognosis of disease. After briefly describing the magnetic resonance imaging (MRI) techniques commonly used, we will describe AI techniques used for the detection of lesions and MS prognosis.</p><p><strong>Results: </strong>We then evaluate the clinical maturity of these AI techniques in relation to MS.</p><p><strong>Conclusion: </strong>Finally, future research challenges are identified in a bid to encourage further improvements of the methods.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"849-858"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1352458520966298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38536622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.","authors":"Amit Bar-Or,&nbsp;Heinz Wiendl,&nbsp;Xavier Montalban,&nbsp;Enrique Alvarez,&nbsp;Maria Davydovskaya,&nbsp;Silvia R Delgado,&nbsp;Evgeniy P Evdoshenko,&nbsp;Natasa Giedraitiene,&nbsp;Katrin Gross-Paju,&nbsp;Sulev Haldre,&nbsp;Craig E Herrman,&nbsp;Guillermo Izquierdo,&nbsp;Guntis Karelis,&nbsp;Fritz Leutmezer,&nbsp;Miroslav Mares,&nbsp;Jose E Meca-Lallana,&nbsp;Dalia Mickeviciene,&nbsp;Jacqueline Nicholas,&nbsp;Derrick S Robertson,&nbsp;Denis V Sazonov,&nbsp;Kenneth Sharlin,&nbsp;Bharathy Sundaram,&nbsp;Natalia Totolyan,&nbsp;Marta Vachova,&nbsp;Martin Valis,&nbsp;Morten Bagger,&nbsp;Dieter A Häring,&nbsp;Inga Ludwig,&nbsp;Roman Willi,&nbsp;Martin Zalesak,&nbsp;Wendy Su,&nbsp;Martin Merschhemke,&nbsp;Edward J Fox","doi":"10.1177/13524585211044479","DOIUrl":"https://doi.org/10.1177/13524585211044479","url":null,"abstract":"<p><strong>Background: </strong>Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved in several countries for relapsing multiple sclerosis (RMS).</p><p><strong>Objective: </strong>To demonstrate the bioequivalence of ofatumumab administered by an autoinjector versus a pre-filled syringe (PFS) and to explore the effect of ofatumumab on B-cell depletion.</p><p><strong>Methods: </strong>APLIOS (NCT03560739) is a 12-week, open-label, parallel-group, phase-2 study in patients with RMS receiving subcutaneous ofatumumab 20 mg every 4 weeks (q4w) (from Week 4, after initial doses on Days 1, 7, and 14). Patients were randomized 10:10:1:1 to autoinjector or PFS in the abdomen, or autoinjector or PFS in the thigh, respectively. Bioequivalence was determined by area under the curve (AUC_<i>τ</i>) and maximum plasma concentration (<i>C</i>_max) for Weeks 8-12. B-cell depletion and safety/tolerability were assessed.</p><p><strong>Results: </strong>A total of 256 patients contributed to the bioequivalence analyses (autoinjector-abdomen, <i>n</i> = 128; PFS-abdomen, <i>n</i> = 128). Abdominal ofatumumab pharmacokinetic exposure was bioequivalent for autoinjector and PFS (geometric mean AUC_<i>τ</i>, 487.7 vs 474.1 h × µg/mL (ratio 1.03); <i>C</i>_max, 1.409 vs 1.409 µg/mL (ratio 1.00)). B-cell counts (median cells/µL) depleted rapidly in all groups from 214.0 (baseline) to 2.0 (Day 14). Ofatumumab was well tolerated.</p><p><strong>Conclusion: </strong>Ofatumumab 20 mg q4w self-administered subcutaneously via autoinjector is bioequivalent to PFS administration and provides rapid B-cell depletion.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"910-924"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/9a/10.1177_13524585211044479.PMC9024029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39483280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.","authors":"Paola Valsasina, Claudio Gobbi, Chiara Zecca, Alex Rovira, Jaume Sastre-Garriga, Hugh Kearney, Marios Yiannakas, Lucy Matthews, Jacqueline Palace, Antonio Gallo, Alvino Bisecco, Achim Gass, Philipp Eisele, Massimo Filippi, Maria A Rocca","doi":"10.1177/13524585211045545","DOIUrl":"10.1177/13524585211045545","url":null,"abstract":"<p><strong>Background: </strong>Spatio-temporal evolution of cord atrophy in multiple sclerosis (MS) has not been investigated yet.</p><p><strong>Objective: </strong>To evaluate voxel-wise distribution and 1-year changes of cervical cord atrophy in a multicentre MS cohort.</p><p><strong>Methods: </strong>Baseline and 1-year 3D T1-weighted cervical cord scans and clinical evaluations of 54 healthy controls (HC) and 113 MS patients (14 clinically isolated syndromes (CIS), 77 relapsing-remitting (RR), 22 progressive (P)) were used to investigate voxel-wise cord volume loss in patients versus HC, 1-year volume changes and clinical correlations (SPM12).</p><p><strong>Results: </strong>MS patients exhibited baseline cord atrophy versus HC at anterior and posterior/lateral C1/C2 and C4-C6 (<i>p</i> < 0.05, corrected). While CIS patients showed baseline volume increase at C4 versus HC (<i>p</i> < 0.001, uncorrected), RRMS exhibited posterior/lateral C1/C2 atrophy versus CIS, and PMS showed widespread cord atrophy versus RRMS (<i>p</i> < 0.05, corrected). At 1 year, 13 patients had clinically worsened. Cord atrophy progressed in MS, driven by RRMS, at posterior/lateral C2 and C3-C6 (<i>p</i> < 0.05, corrected). CIS patients showed no volume changes, while PMS showed circumscribed atrophy progression. Baseline cord atrophy at posterior/lateral C1/C2 and C3-C6 correlated with concomitant and 1-year disability (<i>r</i> = -0.40/-0.62, <i>p</i> < 0.05, corrected).</p><p><strong>Conclusions: </strong>Voxel-wise analysis characterized spinal cord neurodegeneration over 1 year across MS phenotypes and helped to explain baseline and 1-year disability.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"885-899"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Frailty in multiple sclerosis: A closer look at the deficit accumulation framework\".","authors":"Daniele Belvisi,&nbsp;Marco Canevelli,&nbsp;Girolama Alessandra Marfia,&nbsp;Elisabetta Ferraro,&nbsp;Diego Centonze,&nbsp;Marco Salvetti,&nbsp;Antonella Conte","doi":"10.1177/13524585211068150","DOIUrl":"https://doi.org/10.1177/13524585211068150","url":null,"abstract":"Tobia Zanotto 1, Sharon G Lynch2, Jeffrey M Hausdorff 3,4,5,6 and Jacob J Sosnoff 1 1Department of Physical Therapy and Rehabilitation Science, School of Health Professions, University of Kansas Medical Center, Kansas City, KS, USA 2Department of Neurology, School of Medicine, University of Kansas Medical Center, Kansas City, KS, USA 3Center for the Study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 4Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel 5Department of Physical Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 6Rush Alzheimer’s Disease Center and Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1001-1002"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39799796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}